STOCK TITAN

Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company, announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 p.m. ET. The live webcast can be accessed on the company's Investor website, with a replay available for 60 days. Ardelyx is focused on developing first-in-class medicines for kidney and cardiorenal diseases, including tenapanor, which is currently under FDA review for managing serum phosphorus in CKD patients. The company also received FDA approval for IBSRELA® in September 2020.

Positive
  • None.
Negative
  • None.

FREMONT, Calif. and WALTHAM, Mass., May 25, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:30 p.m. ET.  

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelyx, Inc.
Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2020. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2021-virtual-healthcare-conference-301298423.html

SOURCE Ardelyx

FAQ

When will Ardelyx participate in the Jefferies Virtual Healthcare Conference?

Ardelyx will participate in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 p.m. ET.

Who is presenting for Ardelyx at the Jefferies Conference?

Mike Raab, the CEO of Ardelyx, will be presenting at the conference.

How can I access Ardelyx's presentation at the conference?

You can access the live webcast of Ardelyx's presentation on the Events & Presentations page within the Investor section of their website.

What is Ardelyx's main focus in biopharmaceuticals?

Ardelyx focuses on developing innovative first-in-class medicines for kidney and cardiorenal diseases.

What is the status of tenapanor from Ardelyx?

Tenapanor is currently under FDA review for managing serum phosphorus levels in adult patients with chronic kidney disease.

Ardelyx, Inc.

NASDAQ:ARDX

ARDX Rankings

ARDX Latest News

ARDX Stock Data

1.10B
232.36M
1.69%
60.94%
9.84%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FREMONT